Objective-To delineate the clinical phenotype, molecular basis, and implications for screening in patients and families with multiple schwannomas not generally involving the cranium. Methods-As part of a United Kingdom clinical and genetic study of type 2 neurofibromatosis (NF2) patients and families with multiple schwannomas who do not fulfil diagnostic criteria for NF2 have been identified. The clinical phenotype was studied in the extended families and molecular analysis was carried out at the NF2 gene locus on chromosome 22.
Abstract
Objective-To delineate the clinical phenotype, molecular basis, and implications for screening in patients and families with multiple schwannomas not generally involving the cranium. Methods-As part of a United Kingdom clinical and genetic study of type 2 neurofibromatosis (NF2) patients and families with multiple schwannomas who do not fulfil diagnostic criteria for NF2 have been identified. The clinical phenotype was studied in the extended families and molecular analysis was carried out at the NF2 gene locus on chromosome 22. Results-Patterns of inheritance in five families with schwannomatosis are consistent with inheritance of an autosomal dominant gene. The consistency of phenotype, with relative sparing of the cranium, is constant in these families. However, families which initially seem to be indicative of schwannomatosis may develop into classic NF2 as shown by a sixth family. Many of the tumours found in these families were referred to as "neurofibroma" when they were clearly schwannomas. This difference in classification has major implications for the relative risk of each particular type of neurofibromatosis and neuropathological review may be important in some cases. Genetic linkage analysis in the two largest families is entirely consistent with primary involvement of the NF2 gene. Conclusions-Variant forms of neurofibromatosis have presented a dilemma in classification and determination of recurrence risks in families. Previous reports have suggested that schwannomatosis is a sporadic non-hereditary condition. Patients with multiple schwannomas are likely to have a variant form of NF2 and up to a 50% risk of passing on a gene predisposing to multiple schwannoma. The neurofibromatoses consist of at least two distinct dominantly inherited disorders: neurofibromatosis type 1 (NFl) and NF2. These conditions were eventually recognised as separate entities with the localisation of the respective genes to chromosome 17 and 22, and with Table 3 shows seven sporadic cases with three 5-1: genetic distances between the 22q12-2 markers were taken to be as follows: D22S275-1 cM -D22S273 -2cM -D22S280 -1cM -D22S281j NF2CA3 and NF2TET are located within intron 1 of the NF2 gene; D22S268 and D22S430 are located in a 160 kb contig, approximately 300 kb telomeric to the NF2 gene. patients with spinal nerve tumours"3 showed that of 68 patients, 40 had a sporadic schwannoma, two had a sporadic neurofibroma, with 14 patients having NFI and seven NF2. Of the patients with NF1 all had neurofibromas only, whereas six of seven patients with NF2 had schwannomas only. The remaining patient with NF2 had features of both types. A further five patients had either more than one schwannoma or a schwannoma and other CNS tumours. It could be argued that at least three of these patients had schwannomatosis.
SCHWANNOMATOSIS
Schwannomatosis or neurilemmomatosis has been proposed as a separate entity to NFl and NF2.6 14 15 This classification is made largely on the basis of an extensive Japanese literature and 35 cases were reviewed in 1984."4 Of 13 definite cases, seven had eighth nerve symptomatology highly suggestive of vestibular schwannoma, three patients were children, and the other three only in their 20s. Of the four definite new cases reported by Shishiba et al 4 one had bilateral vestibular schwannoma, two were only 8 and 13 years old and although one patient was 45 years old, no radiological exclusion of vestibular schwannoma was performed. Of the remaining 16 probable cases, nine had eighth nerve symptomatology, three were prepubertal, and one was 18 years old with evidence of intracranial disease. Only three patients were over the average age of presentation for vestibular schwannoma in NF2 (20-22 years) '6 17 and all of these were in the pre-CT era. Shishiba et al 14 reported an overall rate for eighth nerve tumour of 15 of 33 and it is highly likely that these patients represented new mutations for classic NF2. The type and range of skin lesions reported were identical with those occurring in NF2. 16 It is also of note that the incidence of glioma in their report was identical to that found in large NF2 series.'6 17 A more recent report of two cases6 contained one clear case of NF2. This patient had bilateral vestibular schwannoma, typical intracranial calcification, ependymomas, and a trigeminal tumour. A rather spurious argument was made that this case lacked the other "cardinal" features of NF and therefore this precluded a diagnosis of NF2. The second case had multiple intracranial meningiomas and although CT of the auditory meatuses were normal the patient was only 20 years old. This patient would therefore fulfil our modified criteria for NF2,"8 and we think it very likely she would go on to develop bilateral vestibular schwannoma. A further American patient aged 60 years with multiple neurilemmomas has been reported, but, there were insufficient clinical data to determine the context in which these tumours occurred.'9 A more convincing recent report of 14 patients with schwannomatosis, who were carefully excluded as having NF2 (no vestibular schwannoma, cataracts, or meningioma) also identified this condition as being distinct from NF2. However, three of the patients were still very young and many others had very localised disease.
Most previous cases of schwannomatosis have been isolated; this report has clearly outlined autosomal dominant inheritance of a tendency to develop multiple schwannomas. This has also been reported by Riccardi4 and Shishiba et al. '4 The question is whether this entity is distinct from NF2. One of the patients from Shishiba et al from the 1984 report5 14 has gone on to develop more classic NF2. The diagnosis of schwannomatosis relies heavily on exclusion of NF2 by the NIH criteria (table 1) .' These criteria rely on the presence of bilateral vestibular schwannoma or a family history. As 50% of people with NF2 are new mutations20 and at least 20% present initially with spinal or cutaneous tumours'7 most, if not all, of the eight patients aged 16 years or under in Shishiba's review14 are likely to develop classic NF2. This is further borne out by our family V, who for many years would have been considered a classic schwannomatosis family until bilateral vestibular schwannoma were diagnosed in two family members. It is therefore likely that the great majority of all the previous cases of schwannomatosis actually represent new mutations for NF2. It is possible that some patients may represent somatic mutations in whom the mutation in the NF2 gene has occurred postzygotically, but may still mean that a significant proportion of cells contains the mutation. This could mean that tumours may be confined to one part of the spine or skin for instance, such as in the study of MacCollin et al. '5 There is a good precedent for this "mosaicism" in NF1 where there are clear patients in whom only part of the body is affected and yet there may still be a risk of transmission to the offspring if the gonads are involved.5 None the less if the patient is young, a diagnosis of classic NF2 is still highly likely and even if they are old and vestibular schwannoma have been excluded on MRI, caution must be exercised about the risks of transmission.
Previous analysis of families with familial spinal neurofibromatosis found linkage to the NF1 locus in one family who also had cafe au lait patches, but exclusion in a second family without other corroborating features of NFI. 21 There was insufficient information to assess linkage to the NF2 locus. These families are likely to be distinct from those exhibiting multiple schwannomas. The first family clearly had NFl with spinal neurofibromas and therefore linkage at this locus was not surprising.
No single family member fulfils the NIH diagnostic criteria for NF1 or NF2 in five of the families reported here. Although at least one family member has developed a cranial nerve schwannoma in three of them. It is likely that the reliance on bilateral vestibular schwannoma as the sole diagnostic criteria for NF2 in sporadic cases has biased all reported cases, leading us to think that there is virtual complete penetrance of this disease feature in NF2. However, even in classic families there are often patients who do not develop vestibular schwannoma late into life.'822 The premise that vestibular schwannoma reaches full penetrance in NF2 would seem to be a false one. It is therefore possible that certain mutations in the NF2 gene, or in a closely linked gene predispose to a different pattern of tumours, with sparse cranial involvement, but many spinal and cutaneous tumours. In some families such as the five we have presented it may be possible to counsel on the basis of a lower risk of cranial tumours, but it would be dangerous to do so in isolated patients with multiple schwannomas. It is likely that there is still an increased risk of eighth nerve tumours in all these families.
We have found no evidence for exclusion of any of these families from the NF2 locus using linked and intragenic markers and indeed have generated a near significant lod score to support involvement of the NF2 this manifestation should no longer be thought of as the "hallmark" of the disease.
